- Home
- PBK vs JSPR Comparison
PBK vs JSPR Comparison
Compare PBK & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBK | JSPR |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 26.3M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PBK | JSPR |
|---|---|---|
| Price | $0.20 | $0.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.00 | ★ $6.38 |
| AVG Volume (30 Days) | ★ 654.4K | 376.2K |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $171.32 | N/A |
| Revenue Next Year | $40.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.32 |
| 52 Week High | $0.86 | $2.51 |
Technical Indicators
Market Signals| Indicator | PBK | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 32.31 | 38.88 |
| Support Level | $0.17 | $0.42 |
| Resistance Level | $0.29 | $0.67 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 21.08 | 25.07 |
Price Performance
Historical ComparisonAbout PBK PowerBank Corporation Common Stock
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.